Jennifer Sandidge

Jennifer Sandidge has a diverse work experience in the pharmaceutical industry. Jennifer started their career in 2007 at Merck as an Assistant Scientist, providing analytical support for inhalation drug products. Jennifer then became a Scientist within the Biopharmaceutics & Respiratory Product Development Group at Merck, where they provided analytical, device, formulation, and process development support.

In 2016, Jennifer joined Teva Pharmaceuticals as a Regulatory Affairs Associate III. Jennifer developed regulatory strategies for post-approval CMC changes to branded combination products and small molecules, leading regulatory submission teams and communicating regulatory strategies to global interdisciplinary project teams.

Jennifer then moved to Vertex Pharmaceuticals in 2018. Jennifer initially served as the Chemistry Manufacturing Controls Senior Manager before transitioning into the role of Manager, Global Regulatory Affairs CMC. In this role, they were responsible for developing and communicating regulatory strategies for post-approval CMC changes and assessing commercial change controls.

In 2021, Jennifer joined Axsome Therapeutics, Inc. as an Associate Director, Regulatory Affairs - CMC. Jennifer continued to contribute to regulatory strategies before eventually transitioning to their current role as an Associate Director, Global Regulatory Sciences CMC at Blueprint Medicines in 2022.

Overall, Jennifer Sandidge has gained extensive experience in regulatory affairs and CMC throughout their career, with a focus on post-approval changes and global submissions.

Jennifer Sandidge, RAC-Drugs, obtained a Bachelor's Degree in Chemical Engineering & Biomedical Engineering from Carnegie Mellon University in the years 2002 to 2006. Jennifer also holds a certification in RAC-Drugs from the Regulatory Affairs Certification Program, which was obtained in December 2021.